

Passionate about animal health____

CONTINUATION OF THE GROWTH TREND IN THE THIRD QUARTER

Public release – October 18th, 2011

Virbac consolidated sales in the third quarter reached 161.0 M \in , a +4.5% change compared to the same period of 2010. Sales increased by +6.7% excluding exchange rates impacts and **+6.0% at constant scope**. This positive evolution is similar to the performance recorded in the second quarter, in spite of the high comparison basis set by the strong same quarters of last year.

After Portugal last May, CaniLeish®, the new Virbac vaccine against canine Leishmaniosis, has been successfully launched in France end of September.

Regionally, Latin America, Asia and Pacific markets have continued to enjoy double digit growth, driven in particular by Brazil, Mexico, India, Australia and South Africa; Europe has also been performing well and in line with the trend observed in the first half. Only the US have experienced a decline this quarter, essentially due to inventory build-ups by distributors in the third quarter 2010.

With total year-to-date sales of 475.5 M \in compared to 438.1 M \in last year, the business trend remains steady with a total increase of +8.5% globally. It is slightly higher (+9.1%) at constant exchange rates. Excluding the impact of recent acquisitions (in Colombia as from early 2011 and in Australia partly in 2010), organic growth accounts for +8.1% for this nine months period.

Regarding market segments by species, year-to-date the companion animals segment records a +6.7% organic growth with a good performance in all product ranges; the food producing animals segment, driven by the dynamics in emerging markets, remains a significant growth contributor with an organic growth of +13.2%, mostly in product categories for bovine (+14.5%) but also to a lesser extent in the industrial sector (swine and poultry: +7.7%).

